Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026

Data ReadoutpositiveSKB500Positive

AI Analysis

Summary

Kelun-Biotech presented first-in-human study data for SKB500, a novel B7-H3 antibody-drug conjugate, at the 2026 ASCO Annual Meeting. The presentation of early clinical data represents a positive development for the company's oncology pipeline.

Clinical Trial Data

Phase

Phase_1

Outcome Details

First-in-human study results presented

Importance:6/10

Sentiment:

0.60

oncologyADCB7-H3first-in-humanASCO 2026

Read the original article

Published by PR Newswire Pharma on June 3, 2026 12:00 AM

Read Original